Abstract:The neurotoxicity associated to the anticancer treatments has received a growing body of interest in the recent years. The development of innovating therapies over the last 20years has led to the emergence of new toxicities. Their diagnosis and management can be challenging in the clinical practice and further research is warranted to improve the understanding of their pathogenic mechanisms. Conventional treatments as radiation therapy and chemotherapy are associated to well-known and under exploration emerging central nervous system (CNS) and peripheral nervous system (PNS) toxicities. The identification of the risk factors and a better understanding of their pathogeny through a "bench to bedside and back again" approach, are the first steps towards the development of toxicity mitigation strategies. New imaging techniques and biological explorations are invaluable for their diagnosis. Immunotherapies have changed the cancer treatment paradigm from tumor cell centered to immune modulation towards an efficient anticancer immune response. The use of the immune checkpoints inhibitors (ICI) and CAR-T cells (chimeric antigen receptor) lead to an increase in the incidence of immune-mediated toxicities and new challenges in the neurological patient's management. The neurological ICI related adverse events (n-irAE) are rare but potentially severe and may present with both CNS and PNS involvement. The most frequent and well characterized, from a clinical and biological standpoint, are the PNS phenotypes: myositis and polyradiculoneuropathy, but the knowledge on CNS phenotypes and their treatments is expanding. The n-irAE management requires a good balance between dampening the autoimmune toxicity without impairing the anticancer immunity. The adoptive cell therapies as CAR-T cells, a promising anticancer strategy, trigger cellular activation and massive production of proinflammatory cytokines inducing frequent and sometime severe toxicity known as cytokine release syndrome and immune effector cell-associated neurologic syndrome. Their management requires a close partnership between oncologist-hematologists, neurologists, and intensivists. The oncological patient's management requires a multidisciplinary clinical team (oncologist, neurologist and paramedical) as well as a research team leading towards a better understanding and a better management of the neurological toxicities.

Management of Neurologic Complications in Patients with Brain and Spine Tumors

Medical management of brain tumors and the sequelae of treatment

Headache Management in Individuals with Brain Tumor

Neurologic Complications in Adult Cancer Survivorship

Advances in treatments of patients with classical and emergent neurological toxicities of anticancer agents

Neurological complications in oncology and their monitoring and management in clinical practice: a narrative review

Neurosurgery for Brain Tumors: Update on Recent Technical Advances

The role of intra-cerebrospinal fluid treatment and prophylaxis in patients with solid tumors

Intraspinal tumors accompanied by hydrocephalus: case report, systematic review, and discussion of treatment strategy.

Neurological complications of modern radiotherapy for head and neck cancer

Review of Current Principles of the Diagnosis and Management of Brain Metastases

Molecular Considerations and Evolving Surgical Management Issues in the Treatment of Patients with a Brain Tumor

Top advances of the year: Neuro-oncology

Managing the cognitive effects of brain tumor radiation therapy

Narrative review-diagnosing and managing malignant epidural spinal cord compression: an evidence-based approach

An introductory review of post-resection chemotherapeutics for primary brain tumors

Molecular Foundations of Primary Spinal Tumors-Implications for Surgical Management.

Molecular foundations of primary spinal tumors—implications for surgical management

Treatment of brain metastases in lung cancer: strategies to avoid/reduce late complications of whole brain radiation therapy

Management of Brain Metastases: A Review of Novel Therapies